Novel 12-LOX Inhibitor Fast Tracked for Heparin-Induced Thrombocytopenia
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
A new oral suspension formulation of Xarelto has also been approved by the FDA.
The geko device is designed to stimulate the common peroneal nerve.
Exposure to higher temperatures may have significantly impacted the efficacy of the recalled product.
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2.
Starting aspirin in patients 60 years or older to prevent a first heart attack or stroke is not recommended.
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure.